GlassScriptPhysician profile
Ahmet Hoke
NPI 1679525232
$104,071.30
in general payments reported to CMS, 2019-2025
7 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $20K · 2021: $19K · 2022: $4,400 · 2023: $7,200 · 2024: $4,489 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Travel and Lodging: $901 · Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,152.50 |
| Travel and Lodging | $901.14 |
| Food and Beverage | $376.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $74,641.07 | 2019-2025 | |
| Genzyme Corporation | $18,750.11 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $7,747.89 | 2025 | |
| Astrazeneca Uk Limited | $2,148.00 | 2025 | |
| F. Hoffmann-La Roche Ag | $725.00 | 2025 | |
| Argenx US, INC. | $59.23 | 2025 | Vyvgart Hytrulo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Hoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.